The Halmosi group [42, 43] reported that treatment with L-2286, a PARP inhibitor, exerts a protective effect in hypertension-induced vascular and myocardial remodelling through modulating the expression and activity of heat shock proteins, Akt-1/GSK-3β, and several PKC isoforms and does not affect the blood pressure measured using the tail-cuff method. The gene discussed is PRRT2; the disease is hypertensive disorder.